The effect of rosiglitazone on ischemia-reperfusion-injury using annexin A5 scintigraphy. A double blind placebo- controlled cross-over study in subjects with the metabolic syndrome

Trial Profile

The effect of rosiglitazone on ischemia-reperfusion-injury using annexin A5 scintigraphy. A double blind placebo- controlled cross-over study in subjects with the metabolic syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2010

At a glance

  • Drugs Rosiglitazone (Primary)
  • Indications Metabolic syndrome
  • Focus Pharmacodynamics
  • Most Recent Events

    • 23 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Aug 2010 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
    • 15 Jul 2009 Status changed from not yet recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top